Eli Lilly Acquires AtaiBeckley for $2.8 Billion in Expansion into Mental Health Therapies
Eli Lilly (NYSE: LLY) reported first-quarter revenue of $19.8 billion, driven largely by its blockbuster weight-loss drugs Mounjaro and Zepbound. While these medications remain central to the company's growth strategy, Eli Lilly is also expanding into mental health through recent acquisitions like AtaiBeckley. On July 16, 2026, Eli Lilly agreed to acquire AtaiBeckley (NASDAQ: ATAI) for $2.8 billion plus up to an additional $1 billion in milestone payments. This acquisition is part of a broader strategy that includes developing new therapies such as Brenipatide and BPL-003—both targeting major depressive disorder—and VLS-01, which is set to release phase 2b data later this year. Although the mental health market may not rival Lilly's core revenue streams in scale, these acquisitions represent a long-term diversification strategy. The company aims to leverage its R&D capabilities and expand into new therapeutic areas with high unmet medical needs.
Topics: acquisitions mental health pharmaceuticals pipeline expansion